IPA — Immunoprecise Antibodies Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapValue Trap

Annual balance sheet for Immunoprecise Antibodies, fiscal year end - April 30th, CAD millions except per share, conversion factor applied.

	2019 April 30th	2020 April 30th	2021 April 30th	R2022 April 30th	2023 April 30th
Period Length:	—	—	—	—	—
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Cash
Cash and Short Term Investments	5.47	2.61	41.8	30	8.28
Net Total Accounts Receivable
Net Total Receivables	1.95	3.75	4.12	3.41	4.42
Total Inventory
Prepaid Expenses
Total Current Assets	9.88	7.7	48.9	37.5	16.8
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	1.64	3.08	4.02	3.56	10.4
Net Goodwill
Net Intangible Assets
Long Term Investments
Other Long Term Assets
Total Assets	28.3	27.3	67	93.6	77.8
Payable / Accrued
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	7.2	7.93	6.07	9.29	5.92
Long Term Debt
Capital Lease Obligations
Total Long Term Debt
Total Debt
Deferred Income Tax
Total Other Liabilities
Total Liabilities	10.3	12.2	10	18.4	20
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	18.1	15.1	56.9	75.3	57.8
Total Liabilities & Shareholders' Equity	28.3	27.3	67	93.6	77.8
Total Common Shares Outstanding